Loxoprofen sodium oral solution with higher safety and preparation method thereof
Patent Information
- Application Number
- CN202410942463.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure BDA0004944586710000041 
Figure BDA0004944586710000051 
Figure BDA0004944586710000052
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a loxoprofen sodium oral solution with higher safety and a preparation method thereof. Background Art
[0002] Loxoprofen sodium was first developed by Daiichi Sankyo Pharmaceutical Co., Ltd. in Japan, and its tablets were approved for marketing in Japan. It is a non-steroidal anti-inflammatory analgesic drug. Loxoprofen sodium is commonly used in rheumatology to treat acute and chronic arthritis such as rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis, rheumatic arthritis, etc.; it can also treat soft tissue rheumatism, such as low back pain, cervical shoulder-arm syndrome, fibromyalgia, frozen shoulder, tennis elbow, etc.; it can also be used to treat some postoperative pain and pain after trauma or tooth extraction, as well as antipyretic and analgesic for acute upper respiratory tract inflammation.
[0003] At present, loxoprofen sodium has been approved in the form of capsules, ordinary tablets, dispersible tablets, patches, gel patches, etc., but the above dosage forms have disadvantages such as slow absorption, low bioavailability, slow onset of action, etc., and tablets and capsules are difficult to meet the needs of the elderly, children and patients with dysphagia. Loxoprofen sodium oral solution (hereinafter referred to as "marketed product") has been approved for marketing in Japan. Due to the low antibacterial efficacy standard of the Japanese Pharmacopoeia, this product does not meet the requirements of the Chinese Pharmacopoeia. Therefore, the antibacterial efficiency of the loxoprofen sodium oral solution needs to be further improved.
[0004] Patent CN115531305A discloses a loxoprofen sodium oral solution and a preparation method thereof, which contains loxoprofen sodium and methylparaben; based on the total mass of the loxoprofen sodium oral solution, the content of loxoprofen sodium is 0.5-0.7wt%; and the mass ratio of loxoprofen sodium to methylparaben is 3-5:1. Preferably, based on the total mass of the loxoprofen sodium oral solution, it contains 0.15±0.02wt% of methylparaben. The invention makes loxoprofen sodium into an oral solution that can be stably stored. Compared with other dosage forms containing loxoprofen sodium, it has the advantages of fast absorption, high bioavailability, and fast onset of action. At the same time, it is convenient to administer and can meet the medication needs of different patients. It improves the antibacterial efficacy of the preparation by increasing the prescription dosage of methylparaben, but excessive dosage of methylparaben will lead to an increase in solution-related substances, and propylene glycol needs to be added as a cosolvent in the prescription, which is not conducive to the stability and safety of the preparation.
[0005] Patent EP2926810A1 discloses a pharmaceutically acceptable excipient selected from solvents, microbial preservatives, buffers, sweeteners, aromatics or mixtures thereof, and its formula includes: 0.1-10% by weight of loxoprofen sodium, 0.01-5% by weight of methyl paraben, 0.01-5% by weight of propylparaben, 2-15% by weight of propylene glycol, 0.1-1% by weight of trisodium citrate dihydrate, 0.01-1% by weight of citric acid, 85-95% by weight of maltitol solution, 0.01-2% by weight of sucralose, 0.1-3% by weight of ammonium glycyrrhizinate, 0.1 to 5% by weight of spices and pure water supplemented to 200 mL at most. This prescription also needs to add solvent / cosolvent propylene glycol, which is not conducive to formulation stability and safety.
[0006] Therefore, it is necessary to develop a loxoprofen sodium oral solution with antibacterial efficacy that meets standards and has higher stability and safety. Summary of the invention
[0007] In view of this, the purpose of the present invention is to provide a loxoprofen sodium oral solution using a low-dose antibacterial agent combination, using the low-dose antibacterial agent combination as an antibacterial agent, and controlling the pH of the oral solution to be 6.7-7.3, not only the antibacterial efficacy of the product is improved, the safety is higher, and the stability of the product can also be improved. At the same time, the loxoprofen sodium oral solution of the present invention can also ensure the good solubility of each component without the need for additional addition of propylene glycol, further improving the safety of the preparation.
[0008] To achieve the above-mentioned purpose of the invention, the technical solution of the present invention is as follows:
[0009] On the one hand, the present invention provides a safer loxoprofen sodium oral solution, which comprises, based on the total mass of the oral solution, 0.5-0.7wt% of loxoprofen sodium, 0.06-0.1wt% of an antibacterial agent, 0.02-0.1wt% of a sweetener, 0.05-0.2wt% of a fragrance, a pH buffer and the balance of water;
[0010] Wherein, the amount of pH buffer is the amount required to adjust the pH value to 6.7-7.3;
[0011] The antibacterial agent is a combination of methylparaben and propylparaben;
[0012] The oral solution does not include a co-solvent.
[0013] Preferably, the pH buffer is selected from at least one of hydrochloric acid, acetic acid, sodium acetate, citric acid and sodium citrate, more preferably at least one of sodium citrate and citric acid, more preferably a combination of sodium citrate and citric acid.
[0014] Preferably, the mass ratio of methylparaben to propylparaben is 2-5:1, more preferably 3-4:1, and most preferably 3-3.5:1.
[0015] Preferably, the antibacterial agent accounts for 0.08-0.1 wt % of the total weight of the oral solution, and more preferably 0.08-0.09 wt %.
[0016] Preferably, the pH value of the loxoprofen sodium oral solution is 6.7-7.1, and more preferably 6.7-6.9.
[0017] Preferably, the sweetener is selected from at least one of sucralose, saccharin sodium, aspartame, acesulfame potassium and sorbitol, and more preferably sucralose.
[0018] Preferably, the fragrance is selected from at least one of peach flavor, orange flavor, apple flavor, grape flavor and strawberry flavor, and more preferably grape flavor.
[0019] Preferably, the oral solution does not require the addition of additional ethanol or propylene glycol.
[0020] Preferably, the loxoprofen sodium oral solution is composed of the following components based on the total mass of the oral solution: 0.5-0.7wt% of loxoprofen sodium, 0.08-0.1wt% of antibacterial agent, 0.02-0.05wt% of sweetener, 0.05-0.15wt% of fragrance, pH buffer and balance water.
[0021] Further preferably, the loxoprofen sodium oral solution, based on the total mass of the oral solution, is composed of the following components: 0.5-0.7wt% of loxoprofen sodium, 0.08-0.1wt% of antibacterial agent, 0.02-0.05wt% of sucralose, 0.05-0.15wt% of grape essence, 0.2-0.3wt% of sodium citrate, citric acid and the remainder of water.
[0022] On the other hand, the present invention provides a method for preparing the loxoprofen sodium oral solution, comprising the following steps:
[0023] Heat water to 65-85°C, add a prescribed amount of antibacterial agent, cool to ≤45°C, add a prescribed amount of loxoprofen sodium, a sweetener and a fragrance, mix well, add a prescribed amount of pH buffer, adjust the solution pH to 6.7-7.3, and obtain the loxoprofen sodium oral solution.
[0024] Preferably, the preparation method comprises the following steps:
[0025] Heat water to 70-80° C., add a prescribed amount of an antibacterial agent, stir until dissolved, cool to ≤40° C., add a prescribed amount of loxoprofen sodium, a sweetener and a fragrance, stir until uniformly mixed, add a prescribed amount of a pH buffer, adjust the solution pH to 6.7-7.3, and obtain the loxoprofen sodium oral solution.
[0026] Preferably, the step of adding the prescribed amount of pH buffer is specifically:
[0027] First, 0.2-0.3 wt% of sodium citrate based on the total weight of the oral solution is added, and then citric acid solution is added to adjust the pH to the target value.
[0028] Further preferably, the mass concentration of the citric acid solution is 0.5-2%, most preferably 1%.
[0029] The beneficial effects of the present invention are:
[0030] (1) The present invention found that when the specific pH is adjusted to 6.7-7.3, the pH of the oral solution is stable during the stabilization period, the impurity content is low, and it meets the quality standards, and there is no need to add too much antibacterial agent or solvent.
[0031] (2) The present invention uses a combination of methylparaben and propylparaben as an antibacterial agent, which has a good antibacterial effect and improves product safety. At the same time, the total amount of the antibacterial agent is relatively small, which can effectively reduce the generation of hydroxyphenyl ester degradation impurities; at the same time, the present invention also finds that reducing the content of methylparaben can reduce the generation of loxoprofen sodium related substances, further improving the stability and quality of the preparation;
[0032] (3) The oral solution prepared by the present invention is colorless and clear. Compared with commercially available products, no additional ethanol or propylene glycol or the like is required as a solvent or co-solvent in the prescription. While ensuring good solubility of each component, the side effects caused by alcohol substances are avoided, thereby further improving the safety of the preparation and reducing the production cost. DETAILED DESCRIPTION
[0033] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present application.
[0034] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the content percentages described below are all weight contents. Unless otherwise specified, it is understood that the reaction is carried out at room temperature.
[0035] Example 1
[0036] The prescription is as follows:
[0037]
[0038] The specific steps of the preparation method of this embodiment are as follows:
[0039] (1) Weighing: Weigh the prescribed amount of raw and auxiliary materials and set aside;
[0040] (2) Liquid preparation: Add 90% of the batch of purified water into the liquid preparation tank, start stirring at a frequency of 30 Hz, heat to 70-80°C, add methylparaben and propylparaben, stir for 15±5 min to completely dissolve, and cool to ≤40°C;
[0041] (3) Add the prescribed amount of sucralose, loxoprofen sodium and grape essence, stir at a frequency of 30 Hz, at a temperature of ≤40°C, and stir for 15±5 min to mix evenly;
[0042] (4) Add the prescribed amount of sodium citrate and stir until it is completely dissolved. Take a sample to measure the pH value of the drug solution; add 1% citric acid solution to adjust the pH to 6.9±0.2 (target value 6.9), and take a sample to test the pH value. Stop stirring, add purified water to the prescribed amount, and continue stirring for 10 minutes to stir the drug solution evenly;
[0043] (5) Filtration: Filter through a 0.45 μm polypropylene filter element;
[0044] (6) Filling: Fill into 10 mL polyester / aluminum / polyethylene pharmaceutical composite film bags, 10 mL / bag.
[0045] Example 2
[0046] The prescription is as follows:
[0047]
[0048] The preparation method is the same as Example 1.
[0049] Comparative Example 1
[0050] The prescription is as follows:
[0051]
[0052]
[0053] The preparation method is the same as Example 1.
[0054] Comparative Example 2 prescription is as follows:
[0055]
[0056] The preparation method is the same as Example 1.
[0057] The prescription of comparative example 3 is as follows:
[0058]
[0059] The preparation method is the same as Example 1.
[0060] Comparative Example 4 prescription is as follows:
[0061]
[0062] The preparation method is the same as Example 1.
[0063] Comparative Example 5
[0064] The difference from Example 2 is that methylparaben is 7 mg, propylparaben is 1 mg, and the rest is the same.
[0065]
[0066] The preparation method is the same as Example 1.
[0067] Results test:
[0068] 1. Investigation of antibacterial efficacy of preparations
[0069] This test was carried out in accordance with the provisions of "General Chapter 1121 Antibacterial Efficacy Test Method" in Part IV of the 2020 edition of the "Chinese Pharmacopoeia", and antibacterial efficacy tests were carried out on Example 1, Example 2, Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, Comparative Example 5 and commercially available products. The results are shown in the table below.
[0070]
[0071]
[0072] Among them, the analytical dosage of the commercially available product methylparaben is 0.7 mg / mL.
[0073] The results show that when the prescription contains only methylparaben and the dosage is 0.7mg / mL and 1mg / mL respectively, the antibacterial efficacy of the product fails, and Escherichia coli, Pseudomonas aeruginosa, and Candida albicans do not meet the standards; when the dosage of methylparaben is increased to 2mg / mL, the antibacterial efficacy meets the requirements. When methylparaben and propylparaben are used in combination, the antibacterial efficacy can meet the requirements when the total dosage of the antibacterial agent is small, and the ratio of methylparaben to propylparaben will also affect the antibacterial efficacy, indicating that the combination of methylparaben and propylparaben has a synergistic effect and can effectively improve the antibacterial efficacy, and their different ratios will also affect the antibacterial efficacy.
[0074] 2. Preparation taste screening
[0075] 10 people were selected to taste the oral solutions prepared in Example 1, Example 2, Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, and Comparative Example 5 and the commercially available product, and scored the taste: "10 points" for good taste, "8-9 points" for good taste, "6-7 points" for average taste, "4-5 points" for poor taste, and less than 4 points for poor taste. The taste scoring results are shown in the following table.
[0076]
[0077] The results showed that when saccharin sodium and grape flavor, sucralose and orange flavor were combined in the prescription, the oral solution tasted bitter and had a poor taste. When sucralose and grape flavor were combined, the taste was significantly better than other sweeteners and flavors, and the taste was better, which could effectively mask the bitter taste of loxoprofen sodium, and the taste masking effect would not change significantly during the shelf life.
[0078] 3. Stability inspection
[0079] In this test, high performance liquid chromatography was used to detect relevant substances in the product, and the stability of Examples 1-2, Comparative Examples 1-6, and commercially available products was investigated at a high temperature of 60°C.
[0080] Related substance detection method: Chromatographic column: octadecylsilane bonded silica gel as filler (Waters XbridgeC18 4.6×250mm, 5μm); mobile phase A: 6.8g / L potassium dihydrogen phosphate solution (adjusted to pH 8.0 with ammonia water); mobile phase B: methanol; flow rate: 1.0mL / min; column temperature: 30℃; detection wavelength: 222nm; injection volume: 20μL; linear gradient elution, elution program:
[0081]
[0082]
[0083] Prepare the test solution and reference solution separately, take amounts and inject them into the liquid chromatograph, record the chromatogram, and the stability results are detailed in the table below.
[0084]
[0085]
[0086] The structures of impurities A and B are the same as those in paragraph
[0004] of the specification of patent CN115236255B.
[0087] According to the stability results, under the influence of 60°C high temperature, the stability of Examples 1 and 2 is better than that of commercially available products and Comparative Examples 1 and 2. The stability results of the embodiments and comparative examples show that the increase in the dosage of methylparaben will promote the production of its degradation products, hydroxybenzoic acid and loxoprofen sodium related substances. In the prescriptions of Comparative Examples 1 and 2, the dosage of methylparaben is relatively high, and the content and growth rate of hydroxybenzoic acid and impurity A in the solution are significantly greater than those in Examples 1 and 2. There is no significant difference between the content of impurity B in Comparative Example 2 and the embodiments, but in Comparative Example 1, that is, when the dosage of methylparaben is 2mg / mL, the content of impurity B in the solution is significantly increased. It can be seen that although increasing the content of methylparaben increases the antibacterial effect of the preparation, it will also cause the related substances to increase rapidly, and the total impurity content will increase, which is not conducive to the stability and safety of the preparation.
[0088] In Examples 1 and 2, a composition of methylparaben and propylparaben is used as an antibacterial agent. At a relatively low total amount, the generation of hydroxybenzoic acid is not only effectively reduced, but also the generation of related substances of loxoprofen sodium is inhibited, the total amount of impurities A and B is reduced, and the product stability is improved; in Comparative Examples 3 and 4, sweeteners and fragrances different from those in Examples 1 and 2 are used, and there is no significant difference in the stability of the preparation. In Comparative Example 5, a composition of methylparaben and propylparaben in a ratio different from that in Examples 1 and 2 is used, and there is no significant difference in the stability of the preparation, but the antibacterial efficacy does not meet the requirements.
[0089] 4. Preparation pH Investigation
[0090] By adjusting the amount of citric acid in the prescription, the stability of the prescription of Example 1 under different pH conditions was investigated. The stability results of the preparation under different pH conditions are shown in the table below. The stability investigation method is the same as 3.
[0091]
[0092]
[0093] Under different pH and 60°C high temperature conditions, the oral solution can ensure colorlessness and clarity. According to the results in the table, the oral solution generally shows a trend that the higher the pH, the faster the degradation rate of hydroxyphenyl esters and the higher the hydroxybenzoic acid content. When the pH is 7.5, under the influence of 60°C high temperature, the growth rate of hydroxybenzoic acid and impurity B in the solution becomes faster, and the content increase becomes larger. On the 10th day, the total impurity content reaches 2.05%. When the pH is 6.5, although the total impurity content is low, the pH of the preparation is unstable and the decline is rapid. On the 10th day, the pH drops to 6.4, which does not meet the preparation quality standards. When the pH of the oral solution is adjusted to 6.7-7.3, not only the pH stability of the product is guaranteed, but also the total impurity content is low, which is more conducive to the long-term storage of the product.
[0094] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A safer loxoprofen sodium oral solution, characterized in that: The oral solution comprises, based on the total weight of the oral solution, 0.5-0.7 wt% of loxoprofen sodium, 0.06-0.1 wt% of an antibacterial agent, 0.02-0.1 wt% of a sweetener, 0.05-0.2 wt% of a fragrance, a pH buffer and the balance of water; Wherein, the amount of pH buffer is the amount required to adjust the pH value to 6.7-7.3; The antibacterial agent is a combination of methylparaben and propylparaben; The oral solution does not include a co-solvent.
2. The loxoprofen sodium oral solution according to claim 1, characterized in that The pH buffer is selected from at least one of hydrochloric acid, acetic acid, sodium acetate, citric acid and sodium citrate.
3. Loxoprofen sodium oral solution according to claim 2, characterized in that, The pH buffer is a combination of sodium citrate and citric acid.
4. The loxoprofen sodium oral solution according to claim 1, characterized in that The mass ratio of methylparaben to propylparaben is 2-5:1, preferably 3-4:1, and more preferably 3-3.5:
1.
5. The loxoprofen sodium oral solution according to claim 1, characterized in that The antibacterial agent accounts for 0.08-0.1 wt % of the total weight of the oral solution, preferably 0.08-0.09 wt %.
6. The loxoprofen sodium oral solution according to claim 1, characterized in that The pH value of the loxoprofen sodium oral solution is 6.7-7.1, preferably 6.7-6.
9.
7. The loxoprofen sodium oral solution according to claim 1, characterized in that The sweetener is selected from at least one of sucralose, saccharin sodium, aspartame, acesulfame potassium and sorbitol.
8. The loxoprofen sodium oral solution according to claim 1, characterized in that The aromatic agent is selected from at least one of peach flavor, sweet orange flavor, apple flavor, grape flavor and strawberry flavor.
9. The loxoprofen sodium oral solution according to any one of claims 1 to 8, characterized in that The loxoprofen sodium oral solution is composed of the following components based on the total weight of the oral solution: 0.5-0.7wt% of loxoprofen sodium, 0.08-0.1wt% of an antibacterial agent, 0.02-0.05wt% of a sweetener, 0.05-0.15wt% of a fragrance, a pH buffer and the balance of water; Preferably, the composition comprises: 0.5-0.7wt% of loxoprofen sodium, 0.08-0.1wt% of antibacterial agent, 0.02-0.05wt% of sucralose, 0.05-0.15wt% of grape essence, 0.2-0.3wt% of sodium citrate, citric acid and the balance of water.
10. The method for preparing the loxoprofen sodium oral solution according to any one of claims 1 to 9, characterized in that: The steps include: Heat water to 65-85°C, add a prescribed amount of antibacterial agent, cool to ≤45°C, add a prescribed amount of loxoprofen sodium, a sweetener and a fragrance, mix well, add a prescribed amount of pH buffer, adjust the solution pH to 6.7-7.3, and obtain the loxoprofen sodium oral solution.
Citation Information
Patent Citations
Preservative composition for liquid pharmaceutical preparation
CN106237337A
Loxoprofen sodium oral solution and preparation method thereof
CN115531305A
Oral liquid pharmaceutical formulations of loxoprofen
EP2926810A1
